Equities

MDxHealth SA

MDXH:NAQ

MDxHealth SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.71
  • Today's Change0.09 / 5.56%
  • Shares traded315.73k
  • 1 Year change-42.23%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 19:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

  • Revenue in USD (TTM)80.74m
  • Net income in USD-40.80m
  • Incorporated2003
  • Employees300.00
  • Location
    MDxHealth SACAP Business Center, Rue d'Abhooz 31HERSTAL 4040BelgiumBEL
  • Phone+32 43642070
  • Fax+32 42597875
  • Websitehttps://mdxhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Armata Pharmaceuticals Inc5.47m-41.36m75.62m66.00------13.83-1.24-1.240.1312-1.410.0518--1.0282,833.34-39.21-59.78-116.66-72.70-----756.59-1,113.72----1.90---17.77---87.03--184.10--
Aerovate Therapeutics Inc0.00-84.61m76.79m51.00--0.954-----2.99-2.990.002.790.00----0.00-72.99---81.83--------------0.00-------46.61------
ESSA Pharma Inc0.00-27.67m76.79m50.00--0.5957-----0.6257-0.62570.002.900.00----0.00-19.33-23.01-19.81-23.67------------0.00------24.27------
Fibrobiologics Inc0.00-17.78m77.64m10.00--27.76-----0.8864-0.88640.000.08070.00----0.00-149.60---225.38--------------0.0403-------272.15------
Chimerix Inc159.00k-83.59m79.14m72.00--0.5829--497.76-0.9351-0.93510.00181.510.0008--1.922,208.33-43.54-30.45-48.29-34.092.52---52,574.84-442.93----0.00---99.04-46.24-147.68---13.24--
CervoMed Inc10.07m-11.95m79.57m8.00--1.74--7.90-1.60-1.601.355.530.3305----1,258,319.00-39.22-53.67-43.28-58.89-----118.68-949.54----0.00------86.07------
Quince Therapeutics Inc0.00-53.26m79.63m32.00--1.77-----1.25-1.250.001.040.00----0.00-50.27-42.72-52.16-46.06------------0.249------39.25---5.47--
Clearside Biomedical Inc7.70m-31.88m79.64m30.00------10.34-0.4503-0.45030.1094-0.46540.2423--9.23256,766.70-100.27-63.57-122.24-81.7797.01---413.83-231.80--------519.89207.341.40--82.41--
Adicet Bio Inc0.00-117.88m79.69m143.00--0.3767-----1.70-1.700.002.570.00----0.00-49.20-37.03-53.58-40.28-------748.46----0.00---100.00---104.41--65.27--
Sellas Life Sciences Group Inc0.00-32.28m79.77m16.00--5.02-----0.7113-0.71130.000.24680.00----0.00-186.64-111.48-527.32-184.29-------1,289.42----0.00---100.00--9.59------
Renovaro Inc0.00-115.69m79.96m25.00--0.8096-----0.9343-0.93430.000.62230.00----0.00-128.97-39.86-158.19-42.11-----------9.650.0259-------103.23---37.12--
MDxHealth SA80.74m-40.80m80.19m300.00------0.9931-1.54-1.543.06-0.32290.59069.397.49269,136.70-29.85-51.62-43.63-64.7262.6450.88-50.54-117.640.8252-1.741.18--89.4319.842.14--30.13--
PMV Pharmaceuticals Inc0.00-51.47m81.24m63.00--0.4105-----0.9998-0.99980.003.820.00----0.00-21.24-21.16-22.36-21.91------------0.00------5.94--16.31--
Inotiv Inc501.06m-99.22m83.49m1.96k--0.4584--0.1666-3.84-3.8419.447.000.6158.126.83256,297.70-12.11-23.84-19.28-29.2624.9329.31-19.70-33.240.2279-0.62340.6774--4.5285.1068.80--83.64--
Allakos Inc0.00-178.75m83.91m131.00--1.15-----2.03-2.030.000.81420.00----0.00-87.64-42.71-97.01-45.11------------0.00------41.96---38.89--
Data as of Nov 21 2024. Currency figures normalised to MDxHealth SA's reporting currency: US Dollar USD

Institutional shareholders

34.74%Per cent of shares held by top holders
HolderShares% Held
Bleichroeder LPas of 30 Sep 20248.38m16.93%
AWM Investment Co., Inc.as of 30 Sep 20244.25m8.59%
Soleus Capital Management LP (Investment Management)as of 30 Sep 20241.11m2.23%
Alyeska Investment Group LPas of 30 Sep 20241.01m2.03%
Monashee Investment Management LLCas of 30 Sep 20241.00m2.02%
Samjo Management LLCas of 30 Sep 2024790.00k1.60%
Heights Capital Management, Inc.as of 30 Sep 2024325.00k0.66%
TD Securities (USA) LLCas of 30 Sep 2024135.09k0.27%
Ghisallo Capital Management LLCas of 30 Sep 2024105.02k0.21%
Maven Investment Partners US Ltd. (US)as of 30 Sep 2024100.15k0.20%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.